No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
Hemorrhage
PI3K inhibitor
anticoagulant
antiplatelet
thrombocytopenia
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
pubmed:
11
12
2020
medline:
1
5
2021
entrez:
10
12
2020
Statut:
ppublish
Résumé
The advent of novel B-cell receptor pathway targeting agents like ibrutinib dramatically changed management of B-cell malignancies. However, with concomitant anticoagulation (AC) and antiplatelet (AP) therapy, ibrutinib is associated with increased bleeding. This
Identifiants
pubmed: 33297794
doi: 10.1080/10428194.2020.1845339
doi:
Substances chimiques
Antineoplastic Agents
0
Purines
0
Quinazolinones
0
idelalisib
YG57I8T5M0
Banques de données
ClinicalTrials.gov
['NCT01282424', 'NCT01539512']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
837-845Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States